Image courtesy of 4Tech Inc.
May 16, 2016 — 4Tech Inc. announced its partnership with Jean-Claude Laborde, M.D., as a research and development (R&D) and clinical advisor focused on fast-forwarding the TriCinch Generation Two and Generation Three programs. The company calls TriCinch the world’s first transcatheter device for repair of the tricuspid heart valve.
Laborde is an internationally recognized cardiologist and one of the world leaders in transcatheter aortic valve implantation (TAVI). He holds numerous patents for novel medical devices that have changed how cardiologists practice medicine and has designed new medical procedures to treat specific cardiac conditions. Laborde is a key opinion leader in interventional cardiology, having spoken around the world about TAVI and other new medical procedures and trained hundreds of physicians internationally.
“Tricuspid regurgitation represents a significant unmet clinical need,” said Laborde, who previously supported the development of the CoreValve device when it was emerging, serving as chief medical officer until CoreValve was purchased by Medtronic in 2009. “4Tech is the sole company that is 100-percent-focused on repairing the tricuspid valve and possesses in-depth knowledge of the tricuspid valve anatomy and pathology. I am very proud to be a part of 4Tech.”
Laborde continues to provide proctoring support for TAVI devices. In addition, he has also been involved in training and teaching cardiologists and interventional cardiologists how to use TAVI devices, how to properly select patients and establish safe and effective protocols for hospitals and clinics.
Laborde was also intimately involved in the development of the Transcatheter Mitral Valve Replacement solution developed by CardiAQ, which was acquired by Edwards Lifesciences in 2015.
For more information: www.4techtricuspid.com
April 01, 2024 
